NEW YORK (GenomeWeb News) - Applied Biosystems said today that it will co-develop and commercialize Olink Bioscience's proximity ligation assay technology under an exclusive license.
ABI said the agreement gives it the right to commercialize the PLA technology for “specific applications” in the life science research market, including biomarker validation and characterization of biological processes.
Olink retains the rights to other applications of the technology, including in situ applications in the life science research market and all rights in the area of in vitro diagnostics.
Under the agreement, ABI will develop products for in vitro PLA applications in a controlled environment. These products will combine PLA’s protein-detection capabilities with ABI’s real-time PCR systems in order to enable protein expression studies using the same instruments and reagents that are typically used for genotyping and gene expression analysis, the company said.
PLA uses two oligonucleotide-labeled antibodies, DNA ligation, and nucleic acid amplification to detect proteins, their modifications, and their interactions in limited samples.
The combined technology will allow researchers to correlate gene expression and protein quantitation on the same platform, ABI said.
Financial terms of the agreement were not released.